Cohen Joshua B
Known title: Co-Chief Executive OfficerCIK: 0001898644
Associated companies
Transaction History
| AMLX | ▼ Sell | Open Market | 29,545 | $950K | 9/10/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 919 | $30K | 9/10/2026 | View on chart |
| AMLX | ▲ Buy | Grant | 60,039 | $0 | 8/18/2026 | View on chart |
| AMLX | ▲ Buy | Grant | 248,865 | $0 | 3/5/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 29,282 | $424K | 3/2/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 15,500 | $228K | 2/2/2026 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 2,818 | $21K | 1/16/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,974 | $27K | 1/16/2026 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 197,182 | $1.5M | 1/15/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 136,193 | $1.9M | 1/15/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 7,715 | $86K | 1/6/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 29,733 | $426K | 9/30/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 200 | $3K | 9/30/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 21,490 | $74K | 3/31/2025 | View on chart |
| AMLX | ▲ Buy | Grant | 180,118 | $0 | 3/6/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 4,595 | $15K | 3/3/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 11,851 | $41K | 2/3/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 7,471 | $30K | 1/6/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 18,589 | $59K | 9/30/2024 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 1,857 | $3K | 9/23/2024 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 34,449 | $54K | 9/12/2024 | View on chart |
| AMLX | ▲ Buy | Grant | 179,850 | $0 | 4/16/2024 | View on chart |
| AMLX | ▼ Sell | Open Market | 4,135 | $77K | 3/5/2024 | View on chart |
| AMLX | ▲ Buy | Grant | 126,667 | $0 | 2/26/2024 | View on chart |
| AMLX | ▼ Sell | Open Market | 5,841 | $95K | 1/9/2024 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 63,694 | $100K | 11/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 96,076 | $3.1M | 3/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 3,924 | $127K | 3/16/2023 | View on chart |
| AMLX | ▲ Buy | Grant | 50,000 | $0 | 3/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 4,122 | $149K | 1/6/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,846 | $68K | 1/6/2023 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 334,520 | $124K | 5/5/2022 | View on chart |
| AMLX | ▼ Sell | Other | 4,870 | $0 | 1/6/2022 | View on chart |
| AMLX | ▲ Buy | Grant | 75,000 | $0 | 1/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026
Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.